Ophthotech Corporation to Report Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on Tuesday, February 26, 2019
NEW YORK--(BUSINESS WIRE)--Feb. 19, 2019--
Ophthotech
Corporation (Nasdaq: OPHT) today announced that it will report its
fourth quarter and full year 2018 financial and operating results on
Tuesday, February 26, 2019. Following the announcement, Ophthotech’s
management team will host a live conference call and webcast at 8:00
a.m. Eastern Time to discuss the Company’s financial results and provide
a general business update.
To participate in this conference call, dial 888-224-1005 (USA) or
323-994-2093 (International), passcode 6840989. A live, listen-only
audio webcast of the conference call can be accessed on the Investor
Relations section of the Ophthotech website at: www.ophthotech.com.
A replay will be available approximately two hours following the live
call for two weeks. The replay number is 888-203-1112 (USA Toll Free),
passcode 6840989.
About Ophthotech Corporation
Ophthotech is a biopharmaceutical company specializing in the
development of novel therapies for diseases of the eye. For more
information, please visit www.ophthotech.com.
Forward-looking Statements
Any statements in this press release about Ophthotech's future
expectations, plans and prospects constitute forward-looking statements
for purposes of the safe harbor provisions under the Private Securities
Litigation Reform Act of 1995. Actual results may differ materially from
those indicated by such forward-looking statements as a result of
various important factors. Any forward-looking statements represent
Ophthotech's views only as of the date of this press release. Ophthotech
anticipates that subsequent events and developments will cause its views
to change. While Ophthotech may elect to update these forward-looking
statements at some point in the future, Ophthotech specifically
disclaims any obligation to do so.
OPHT-G
View source version on businesswire.com: https://www.businesswire.com/news/home/20190219005045/en/
Source: Ophthotech Corporation
Investors
Kathy Galante
Ophthotech Corporation
Vice
President, Investor Relations and Corporate Communications
212-845-8231
kathy.galante@ophthotech.com
Media
Alex Van Rees
SmithSolve LLC on behalf of
Ophthotech Corporation
973-442-1555 ext. 111
alex.vanrees@smithsolve.com